The Swedish biopharmaceutical company has announced the appointment of two new members to its Board of Directors, Tara Heitner and Pete Zorn.
“We are excited to welcome Tara and Pete to our Board,” says Adam Bruce, Founder and Chairman of the Board of TikoMed in a press release. “Tara and Pete are perfect fits for our next steps with their strong track records of transactional experience. They bring years of organizational and business development expertise and leadership that will serve the company well as we aim to grow our business focused on the ILB® drug platform and take TikoMed to the next level.”
Tara Heitner, PhD, MBA has more than 15 years of international experience in the biopharmaceutical industry. Her experience includes the development and commercialization of early-stage drug discovery technologies to large pharma business development. Dr. Heitner earned a PhD in Chemistry from McGill University in Montreal, Canada and earned an executive MBA from Danish Technical University in 2014.
Read more: Interview Tara Heitner – CEO ISD Immunotech
Pete Zorn is an experienced biopharma business and legal executive with a two-decade history of company-building corporate development and substantial experience with the going public process in the United States. Mr Zorn is currently President and Chief Legal Officer at Genevant Sciences, Inc., and prior to joining Genevant, served as Chief Corporate Officer and General Counsel of Albireo Pharma (NASDAQ: ALBO) and General Counsel for both Santaris Pharma (acquired by Roche) and Targacept (acquired by Catalyst Biosciences). He earned an undergraduate degree from Harvard University and holds a law degree from the University of North Carolina at Chapel Hill.
In connection with these additions, Adam Bruce, founder of TikoMed, is assuming the position as Chairman of the Board.
Photo of Tara Heitner and Pete Zorn